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A B S T R A C T
Antibodies are antigen recognizing immunoglobulins with an amazingly diverse repertoire in the antigen speciﬁc
domain. The diversity of the antibody response is further increased by modiﬁcations such as somatic re-
combination and hypermutation. Furthermore, variation in the isotype and post-translational modiﬁcations such
as Fc glycosylation further increase diversity of the eﬀector functions. In particular variations in the glycan
structures contribute signiﬁcantly to the functional capacities of the antibodies. This is of particular interest
given the dynamic nature of these modiﬁcations that is strongly inﬂuenced by the inﬂammatory environment.
Intriguingly, the glycan proﬁle of antibodies has been unravelled in great detail in inﬂammatory (auto)im-
mune diseases but received only limited attention in the area of infectious diseases and vaccination. Here, we
reviewed the current knowledge on immunoglobulin glycosylation and speciﬁcally focussed on studies in the
ﬁeld of infectious diseases and vaccination against infectious diseases, an area with a lot of interesting oppor-
tunities.
1. Antibody structure and function
Since the origin of uni- and multi-cellular organisms, the release and
secretion of anti-microbial peptides has played a key role in cell and
organismal survival by driving cell:cell communication and pathogen
evasion. Among the pathogen-targeting secreted proteins, antibodies
represent an evolutionary marvel, enabling both pathogen-adaptable
recognition, and providing a mechanism for exquisitely speciﬁc in-
structions to the innate immune system to direct immune cell function
and regulate inﬂammation. These functions are tightly regulated
through the co-evolution of 2 separate protein-domains, the
Fragment:antibody binding (Fab) and the Fragment:crystallizable (Fc)
domain of an antibody, each responsible for directing the bi-functional
activity of these molecules.
Antibodies arose approximately 500 million years ago in the jawed
ﬁsh [1], enabling the generation of highly diverse repertoires of an-
tigen-recognizing immunoglobulins that serve as both antigen targeting
and eﬀector molecules in a single molecule. The emergence of these
molecules enabled an adaptive opportunity to not only recognize pa-
thogens directly and provide a cellular basis for immunological memory
upon re-encounter, but also to provide a means to enable the adaptive
immune response to direct the biological activity of the innate immune
system, through complement or Fc-receptors, which are expressed on
all innate immune cells. Further evolutionary events led to develop-
ment of machinery that enables remarkable structural diversiﬁcation of
the antigen-binding domain of antibodies, via somatic recombination
and hypermutation [2], but also through the capacity to link these
unique antigen-binding domains to one of many diﬀerent possible Fc-
domains [3], each endowed with their own functionality.
Antibodies are heterodimeric glycoproteins, and were ﬁrst reported
by von Behring and Kitasato [4] in 1890 as serum molecules able to
neutralize diphtheria toxin. Antibodies are composed of two identical
heavy chains (H) and two identical light chains (L), held together by
inter-chain disulﬁde bonds [5] (Fig. 1). Each heavy and light chain
possesses a variable (V) N-terminal region (VHor VL), consisting of 3
hypervariable regions, also known as complementary determining re-
gions (CDR) [6,7]. The variable domains are in turn recombined with
one of 9 diﬀerent Fc constant domains [8], each able to interact with
the immune system in a distinct and diﬀerent manner [9,10], thereby
directing the eﬀector functions of the antibody molecule. The posi-
tioning of the disulﬁde bones between heavy and light chains, creates a
Y-like shape, that is further stabilized by a ﬂexible hinge region, that
vary among the Fc-variants [10]. This gives rise to structural diversity
in Fab arm ﬂexibility, allowing the identical Fab arms to move freely,
while binding to identical epitopes, providing bi-valent binding, and
avid interactions [5]. In contrast, the Fc domain of the antibody can be
classiﬁed into one of 5 isotypes: in humans these are IgD, IgM, IgG, IgA,
and IgE [9], each mediating unique eﬀector functions within distinct
anatomical compartments, thus directing distinct eﬀector functions.
Moreover, among the isotypes, further diversiﬁcation exists in humans,
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with 4 subclasses of IgG (1, 2, 3, 4) and 2 for IgA (1 and 2) each with
additional structural diﬀerences and related innate immune receptor
binding, complement activation, or transport across mucosal surfaces.
However, beyond this protein diversiﬁcation, immunoglobulins as
glyco-proteins also vary in numbers of glycosylation sites [5,11]
(Fig. 1). For most immunoglobulins, alterations in glycosylation reg-
ulates structural stability and half-life [12,13]. Moreover, like most cell
surface and secreted proteins, glycosylation varies widely, depending
on the inﬂammatory state [14]. However, unlike other proteins, these
changes contribute directly to altered eﬀector function [12,13], oﬀering
an additional dimension of antibody functional diversity. Remarkably,
changes in IgG glycosylation have been observed across health and
disease [15,16], with dramatic changes noted in antibody glycosylation
with age, during pregnancy, across geographic areas [17,18], and even
among the sexes [17,19–22]. Antibody glycosylation varies further-
more in a speciﬁc IgG subclass-dependent manner, aimed at selectively
regulating speciﬁc antibody functions [23,24]. Additionally, profound
changes in IgG glycosylation have been observed in autoimmune [25],
infectious [26], and malignant diseases [22,27–29]. Because these
changes in glycosylation have been causally linked to altered Fc-ef-
fector function for IgGs [12], the monoclonal therapeutics ﬁeld has
begun to extensively exploit these IgG modiﬁcations to improve eﬀector
function for therapeutic purposes.
2. Antibody glycosylation
Glycosylation of proteins is a remarkably dynamic posttranslational
modiﬁcation that governs the biology of the majority of cell surface and
secreted proteins [14,30]. Speciﬁcally, glycosylation can impact se-
cretion, stability, solubility, packing, binding, conformation, biological
activity, and antigenicity [30]. Because antibody glycosylation is not
templated, but inﬂuenced by immune state, it is a remarkably adaptive
process, creating an unprecedented level of microheterogeneity in
proteins, which endow proteins with a broader range of potential
functional roles, some silent, some subtle and some more profound
[11,14]. Critically, variation in protein glycosylation is conserved and
not random under normal physiological conditions, and variation is
reproducible and controlled [26,31], following speciﬁc patterns when
perturbed [32–34], suggesting exquisite control of this biological pro-
cess. Glycans are added to proteins through one of 2 molecular linkages,
linkages on asparagine residues (N-glycans) or on serine/threonine re-
sidues (O-glycans) [30]. However, unlike other proteins, to which
dozens of diﬀerent N- or O-linked glycans may be added, a stricter re-
pertoire of N-linked glycans can be coupled to IgG [26,30]. Im-
portantly, all IgG species are glycosylated at a single asparagine-297
residue in the Fc-domain of the IgG antibody, to which one out of 30
documented structures can be attached, which are known to have an
essential role on antibody structure and eﬀector function [12,13]. Ad-
ditionally, approximately 20% of Fab domains can evolve to include a
N-linked glycan site [35]. However, this site is glycosylated more uni-
formly, with a more restricted glycan proﬁle than that found in the Fc-
domain of the antibody.
The antibody glycan is composed of a biantennary core hepta-
saccharide composed of a chain of 2 n-acetylglucosamine (GlcNAc)
residues, followed by a mannose, followed by a 1,3 and a 1,6 mannose
branching and an additional GlcNAc residue on each mannose [30]
(Fig. 1). Then variable addition of a fucose, a bisecting GlcNAc, two
galactoses, and two sialic acids residues to the core sugar forms the
basis of antibody glycan diversity [11] of which 30 structures have been
observed in healthy human plasma. Bisection, the addition of an extra
GlcNAc to the core mannose, hampers fucosylation by steric hindering
of the antibody, thereby enhancing functionality of the antibody.
Glycan diversity can be classiﬁed based on their inﬂammatory and
functional capacity [25]. Speciﬁcally, heterogeneous glycans can be
classiﬁed based on their level of galactose incorporation, as glycans that
have no galactose residues (G0), one galactose residue (G1), or two
galactose residues (G2). Striking enrichment of agalactosylated (G0)
glycans is observed in inﬂammatory diseases [25] (Fig. 2). Conversely,
elevated levels of galactosylation are associated with reduced in-
ﬂammatory activity in antibody preparations [16,36].
Galactosylation shows unique age-distributions with G0 antibodies
enriched in the very young [20] and the elderly [21,22,24] (Fig. 3).
Moreover, levels of galactosylation increase during pregnancy, with a
signiﬁcant increase in galactosylation and sialylation and decreased
bisection that normalizes post-partum [19,37,38]. Furthermore, Fc-
glycosylation also varies signiﬁcantly across geographic regions of the
Fig. 1. The Antibody and its glycan. IgG1 are glycosylated at asparagine-297 in
the Fc-domain, to which one of 30 documented structures can be attached,
known to have an essential role on antibody structure and eﬀector function The
antibody glycan is composed of a biantennary core heptasaccharide composed
of a chain of 2 n-acetylglucosamine (GlcNAc) residues (blue squares), followed
by a mannose (green circle), followed by a 1,3 and a 1,6 mannose branching
and an additional GlcNAc residue on each mannose. Variable addition of an
additional fucose (red triangle), an additional bisecting GlcNAc, up to 2 ga-
lactoses (yellow circle) or up to 2 sialic acids (purple triangle) then give rise to
antibody microheterogeneity.
Fig. 2. The functional consequences in anti-
body glycan changes. Changes in galactosyla-
tion have been observed across a multitude of
human diseases, linked to alterations in anti-
body inﬂammatory activity. Speciﬁcally, an
accumulation of agalactosylated antibodies
observed across inﬂammatory diseases (auto-
immunity, infections, malignancy), whereas
increased galactosylation is associated with
less-inﬂammatory conditions (pregnancy).
Moreover, speciﬁc glycan changes have been
exploited in the monoclonal therapeutics ﬁeld
demonstrating the critical role of glycans in shaping antibody eﬀector function. For example, removal of fucose reproducibly enhances ADCC activity, whereas
changes in bisecting GlcNAc alone have a more modest eﬀect. Additionally, sialylation reproducibly enhance the anti-inﬂammatory activity of IVIG in vivo.
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world [18], and again is dramatically altered in autoimmune [25], in-
fectious [26], and oncological diseases [22,27,29] (Fig. 3).
Beyond alterations in galactosylation, the removal of fucose [39]
has been clearly linked to improved antibody-dependent cellular cyto-
toxicity [40,41] (Fig. 2). Likewise, improvement of ADCC has also been
linked to the addition of a bisecting GlcNAc, though this improvement
is related to the indirect loss of fucose upon addition of a bisecting
GlcNAc [42] (Fig. 2). Moreover, because each Fc domain is glycosy-
lated, and each arm may possess a diﬀerent glycoform, heterogeneity is
further increased across IgG antibodies in a polyclonal pool. Variable
addition of glycans give rise to a diverse set of glycoforms that aﬀect
stability, pharmacokinetics, distribution by altering the shape of the Fc-
backbone, all ultimately impacting antibody function by altering Fc-
interactions with a wide array of innate immune receptors or comple-
ment that regulate innate immunity [9].
3. Antibody glycosylation and function
IgG antibodies are able to deploy eﬀector functions following Fc-
binding to both type 1 and 2 Fc-receptors found on all innate immune
cells, or classical or non-classical initiators of the complement cascade
[43] (Fig. 4). In humans, 3 Fc-receptor groups exist that interact with
IgG, including 1 high aﬃnity FcγR1, and 2 low aﬃnity Fc-receptors
including FcγR2 and FcγR3 [9,44]. Moreover, three variants of FcγR2
exist, including 2 activating variants: FcγR2a expressed in all humans
and FcγR2c only expressed in a fraction of the population due to a splice
polymorphism; and an inhibitory variant, FcγR2b. Similarly, two var-
iants of FcγR3 exist, including a transmembrane activating FcγR3a and
an activating GPI anchored variant of this Fc-receptor, FcR3b. Ad-
ditionally, high and low aﬃnity polymorphic variants have been
identiﬁed for both FcγR2a and FcγR3a [45]. In addition, IgG is also able
to interact with the classical initiator of the complement cascade, C1q
to drive both direct cytotoxicity as well as direct immunoregulatory
functions [46]. Furthermore, complexed antibodies have also been
implicated in binding to non-classical Fc-receptors, lectin like receptors,
including DC-SIGN [47], CD22 [48], CD23 [49,50], etc. (Fig. 4) Thus,
because IgG antibodies are able to interact with a remarkably broad
array of receptors/proteins, expressed broadly across immune and non-
immune cells, antibodies have the capacity to direct and regulate the
immune system broadly. However, with our growing appreciation of
the role of both immune-protective and -pathological antibodies in
disease, it is plausible that antibodies, and speciﬁcally complexes of
antibodies, may interact with an even broader array of receptors than
currently known.
Importantly, most antibody interactions with canonical and non-
canonical receptors/proteins are low-aﬃnity, requiring complexes of
antibodies [44], rather than single antibodies, to bind simultaneously in
order to drive highly avid interactions and subsequent cellular activa-
tion. Cellular activation can then drive phagocytosis, antibody depen-
dent cellular cytotoxicity (ADCC), complement dependent cytotoxicity
(CDC), neutrophil activation, etc., all of which are abrogated by IgG
deglycosylation [12]. However, as mentioned above, IgG crystal
structures demonstrate that the IgG glycan is tucked snuggly between
the 2 CH2 domains of the antibody [51,52], and early crystal structures
suggested that the Fc-glycan made minimal contacts with Fc-receptors,
despite the fact that removal of the glycan resulted in the abrogation of
IgG binding to Fc-receptors. Conversely, removal of fucose has a pro-
found impact on modulating FcγR3a binding [39], through a gly-
can:glycan interaction with a second fucose attached to the Fc-receptor
[53]. However, beyond fucose interactions, the glycan contributes
signiﬁcantly to the Fc-conformation, where larger more processed
glycans show the widest conformation, that then enables diﬀerential
binding to both canonical and non-canonical Fc-receptors/proteins
[52]. Additionally, highly galactosylated IgG trigger enhanced com-
plement activity through C1q binding [41,54]. However lack of ga-
lactosylation may also make GlcNAc residues more accessible for
mannose-binding protein (MBP) binding and thus activation of the al-
ternative complement cascade [55]. Thus, complex roles exist for dis-
tinct sugar modiﬁcations, that ﬁnely tune the shape of IgG Fc, enabling
unique interactions with Fc-receptor or Fc-receptor like proteins. Yet
the functional consequences of these diﬀerent binding proﬁles are most
clearly illustrated in the context of disease.
4. Antibody glycosylation and anti-inﬂammatory activity
IgG glycosylation changes have been widely documented across
autoimmune diseases [15,25]. Speciﬁcally, altered glycosylation has
been observed in rheumatoid arthritis [19,37,38,56–61], lupus [62],
multiple sclerosis [63,64], diabetes [65], Sjogren’s disease [66], in-
ﬂammatory bowel disease [29,67,68], alzheimer’s [69], myasthenia
gravis [70], and Guillain-Barre [71]. Speciﬁcally, autoimmune diseases
are largely associated with a dramatic, common, and signiﬁcant loss of
galactosylation, likely related to the critical linkage between changes in
IgG galactosylation and generalized immune activation [72]. While
Fig. 3. Galactosylation in health and disease.
Changes in galactosylation have been widely
documented across health and disease.
Groundbreaking work pointed to an interesting
distribution of glycans across the ages, with
increased levels of inﬂammatory – agalactosy-
lated- antibodies in early life, which re-
emerged with age. Moreover, compelling evi-
dence points to an accumulation of agalacto-
sylated antibodies with inﬂammaging- which
may be unlinked from numerical age. Finally,
agalactosylated antibodies accumulate across
inﬂammatory diseases of dramatically diﬀerent
etiologies, but decrease in anti-inﬂammatory
states, such as pregnancy.
Fig. 4. The landscape of antibody-Fc binding
receptors. Beyond canonical Fc-receptors,
mounting evidence supports a broader role of
additional lectin-like proteins in interacting
with immune complexes and deploying a
broader array of antibody functions including
both activating and inhibitory activities.
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glycosyltransferases and glycosidases are elevated in autoimmune, in-
ﬂammatory diseases, changes in antibody glycosylation do not correlate
with changes in circulating enzymes [73]. Instead, transcriptional
changes in enzymes [50,74] and alterations in sugar precursors have
been observed in the setting of disease, potentially regulating antibody
glycan levels at an intracellular level [75]. However, since the in-
ﬂammatory changes are conserved across distinct autoimmune diseases
of highly diverse etiologies, it is likely that generalized inﬂammation
regulates galactosylation in a common and universal manner. Given the
intimate role of galactosylation in tuning antibody eﬀector function,
including complement activity, it is plausible that alteration in ga-
lactose levels is a non-speciﬁc mechanism exploited across diseases to
rapidly drive immune complex clearance. However, because these
complexes persist, chronic immune activation likely also contributes to
the pathology of many autoimmune disease.
However, signiﬁcant diﬀerences in antibody glycosylation are ob-
servable on antigen-speciﬁc antibodies and within disease-speciﬁc
compartments. Speciﬁcally, changes in anti-citrullinated protein-spe-
ciﬁc antibody (ACPA) Fc-glycosylation, but not Fab-glycosylation [76],
both preceded and predicted the recurrence of autoimmune ﬂares [59]
and the amelioration of symptoms and disease activity [19,37,57].
Moreover, beyond antigen-speciﬁc diﬀerences, Fc-glycosylation
changes are more profoundly altered at the site of disease, where more
dramatic diﬀerences are observed in IgG Fc-glycosylation in the syno-
vium during rheumatoid arthritic disease [60] and within the cere-
brospinal ﬂuid in multiple sclerosis [64].
Beyond their roles as biomarkers, the biological role of IgG glyco-
sylation was most clearly demonstrated in a number of autoimmune
mouse models [16,25]. Interestingly, injection of endoglycosidase S
(EndoS), that removes the majority of the Fc-glycan excluding the ﬁnal
core GlcNAc, resulted in signiﬁcantly attenuated immunopathology and
tissue injury in a number of autoimmune mouse models [77]. Similarly,
in the lupus-prone BXSB mice, eﬃcient removal of the serum IgG Fc-
glycan with EndoS did not alter the production of disease associated
antibodies, including anti-dsDNA or ANA-speciﬁc antibodies, but did
prevent glomerulonephritis and improved survival [78,79]. Ad-
ditionally, IgG galactosylation was shown to contribute to FcγR3-
mediated autoimmune hemolytic anemia [36] whereas highly ga-
lactosylated IgG1, but not other subclasses, reduced inﬂammation in a
complement dependent manner, via the inhibitory FcγR2b and lectin-
like Dectin-1 receptors [80]. Furthermore, sialic acid residues have
been extensively associated with reduced inﬂammation and pathology.
For example, terminal sialylation was associated with reduced FcγR3
binding and reduced platelet clearance in a mouse model of thrombo-
cytopenia [81] and to signiﬁcantly reduce ADCC activity [82,83] and
complement activity [84] in vitro via reduced binding to Fc-receptors
[85].
Most revelatory, the broad impact of intravenous gammaglobulin
(IVIG) has clearly illustrated the critical nature of antibody glycosyla-
tion on inﬂammation. Speciﬁcally, IVIG is used widely to treat a large
number of autoimmune, infectious, and inﬂammatory diseases [16].
The anti-inﬂammatory properties of this mix of polyclonal antibodies
from thousands of blood donors is driven by a small subset of antibodies
that harbor α2,6-sialylation [81,85]. Speciﬁcally, removal of the Fc-
glycan with PNGaseF resulted in reduced immunoprotective activity,
which was additionally recapitulated with the removal of sialic acid
residues alone, using neuraminidase. Thisclearly implicates sialylation
of IVIG as the key to anti-inﬂammatory activity of the IgG Fc-glycan.
Remarkably, dissection of the biological mechanism of this anti-in-
ﬂammatory activity pointed to a complex network of interactions
where sialylated IgG required the c-type lectin receptor SIGN-R1 (spe-
ciﬁc intracellular adhesion molecule-grabbing non-integrin R1) or the
human orthologue DC-SIGN (dendritic-cell-speciﬁc ICAM-3 grabbing
non-integrin), that was linked to the induction of a novel Th2 response,
marked by interleukin-33 secretion (IL-33) [85,86]. A similar interac-
tion between SIGN-R1 and IVIG has been observed in a mouse model of
immune thrombocytopenia (ITP) [85]. Moreover IVIG has also been
linked to reduced B cell activation via direct interactions with CD22
during B cell signalling [85]. However, precisely how polyclonal IVIG
competes with disease-speciﬁc antibodies, that are likely found in
complexes, is unclear, but both in vivo and in vitro data clearly high-
light the critical role of IVIG glycan proﬁles in driving the disease
modifying activity of this surprisingly eﬀective treatment.
5. Antibody glycosylation and infection
Like autoimmune diseases, chronic infections also induce chronic
inﬂammation, and are marked by a loss of galactosylated antibodies
[74,87,88], likely also linked to infection associated immune activa-
tion. Speciﬁcally, an expansion of agalactosylated IgG antibodies was
observed in HIV-infected individuals compared to healthy controls.
Strikingly higher levels of agalactosylated antibodies were observed in
HIV compared to autoimmunity [87]. Moreover, further studies high-
lighted that this expansion of agalactosylated antibodies occurred in
both individuals with progressive HIV infection oﬀ therapy as well as in
those that spontaneously control HIV infection, despite lower levels of
immune activation in the “controllers”. Moreover, unlike in pregnancy
and autoimmunity, where glycosylation changes resolve post-partum or
after ﬂare termination, respectively, agalactosylated antibody levels did
not revert following anti-retroviral therapy, despite a reduction in im-
mune activation due to the elimination of circulating virus [74]. These
data argue that infection, unlike pregnancy and autoimmunity, likely
perturb the B cell compartment, resulting in permanent changes in
antibody glycosylation, reﬂecting a permanently more inﬂamed anti-
body glycome. Interestingly, altered antibody glycosylation was also
observed in Mycobacterium tuberculosis (Mtb) infection, however, gly-
cosylation shifted with disease severity, with an accumulation of aga-
lactosylated glycans in individuals with active Mtb infection and
normal levels of galactosylation in individuals with latent, controlled,
Mtb infection [88]. These data suggest that unlike HIV infection which
appears to irreversibly aﬀect the humoral immune response [89], an-
tibody glycosylation appears to not be irrepairably altered in the con-
text of Mtb infection. Whether irreversible changes occur across other
diseases, with respect to antibody glycosylation is uncertain, but could
point to the mechanism(s) by which antibody glycosylation is regulated
at a molecular level within B cells.
Beyond inﬂammatory glycan changes, additional changes were
observed within the antigen-speciﬁc antibody compartment, associated
with enhanced functionality, in both HIV and Mtb infections. Both
agalactosylation and afucosylation were enriched in HIV-speciﬁc anti-
bodies among spontaneous controllers of HIV, and were linked to en-
hanced NK cell activity [74]. Similarly, latently infected Mtb controllers
also exhibited an expansion of afucosylated antibodies, which were also
able to drive enhanced NK cell activity and bind more eﬀectively to
FcγR3a [88]. These data suggest that for both of these intracellular
infections, where antibody-dependent cellular cytotoxicity may be key
to infected cell control and clearance, antigen-speciﬁc antibody glyco-
sylation may be selectively skewed to promote more eﬀective destruc-
tion of the pathogen. Thus collectively, these data highlight similar
changes in bulk IgG glycosylation in infectious diseases similar to those
observed in autoimmune disease, however antigen-speciﬁc glycosyla-
tion appears to be directed in a deliberate manner during infection,
enabling individuals who control their infections by driving enhanced
antibody functionality. These exciting data strongly argue for im-
munological control of antibody glycosylation, and suggest that vacci-
nation may have the capacity to harness the unexplored functional
potential of the antibody Fc-domain via glyco-regulation.
6. Vaccination and antibody glycosylation
Vaccination against infectious diseases has been initiated in the late
1800 s by Edward Jenner, who discovered protection against smallpox
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be exposing people to the related cow pox virus. Although the me-
chanism of protection remained elusive for a considerable time, the use
of a related virus to reduce the burden and incidence of an infection like
smallpox was a giant step forward for global health. Subsequent vac-
cination strategies were based on isolation of the pathogens, inactiva-
tion and injection, and more recently live attenuated pathogens were
replaced by antigenic fragments [90]. Vaccine induced protection
against most pathogens depends on the induction of neutralizing anti-
bodies, in particular for protection against most viruses. More complex
pathogens may require additional (cellular) protective mechanisms.
Several of the vaccines that have been developed many years ago are
still used on a daily basis. For example, BCG (Bacillus Calmette Guerin)
the vaccine against tuberculosis (TB) was developed in the 1920 s and is
still administered to newborns in large parts of the world.
Vaccine induced antibodies often act through neutralization of cri-
tical antigens for cell entry, such that antibody binding inhibits infec-
tion and contributes to elimination of the pathogen (Fig. 5). Moreover,
antibody binding to pathogens may contribute to opsonisation and
subsequent clearance of the pathogen. Antibody neutralization appears
highly eﬃcient for small pathogens such as most viruses but seems less
eﬃcient in case of more complex pathogens such as parasites and (in-
tracellular) bacteria.
Studies on vaccine induced antibodies have comprised not only
analysis of antigen recognition and viral neutralization but also the
characterization of the properties of the antigen speciﬁc antibodies.
However, in contrast to the highly detailed characterization of an-
tibody properties in health and disease only a limited number of studies
have assessed the glycosylation proﬁles of antibodies evoked by vac-
cination. Antibody induction by vaccination not only depends on the
speciﬁc vaccine antigen, but also the adjuvant used, which will inﬂu-
ence antibody properties, including glycosylation patterns. Moreover,
depending on the type of vaccine single or multiple doses are required
to induce optimal protection, but subsequent B-cell activation by
booster vaccination may not only increase antibody levels but may also
alter glycan structures.
Thus vaccination is an interesting “model” to assess glycosylation
proﬁles and learn about in vivo regulation of glycosylation mechanisms
and phenotypes. Firstly, the antigen and immune-activating adjuvant
can be controlled and compared. Antibody responses to single re-
combinant antigens may be functionally completely diﬀerent from an-
tibodies formed in response to complete pathogens, either live atte-
nuated or killed. Multiple diﬀerent vaccine antigens can be
administered simultaneously to compare regulation of glycosylation by
the antigen rather than the host. Secondly, priming vs. booster re-
sponses can be compared. Priming vaccines represent the ﬁrst exposure
of the immune system to the particular antigen. In contrast to the
permanent persistence of autoantigens or the long-term exposure to
tumour-derived antigens, antigens in vaccines may be cleared from the
body and thus only temporarily trigger the immune system. It would be
highly interesting to assess the stability of glycosylation stages for an-
tigens that are only temporarily present. In addition, re-exposure to the
antigen may modify the glycosylation proﬁle, and this process might be
evoked by revaccination or subsequent encounter of the pathogen.
Thirdly, in a vaccination setting the time since primary antigen en-
counter is known and responses can be monitored over time. Booster
vaccinations may not only alter the magnitude of the antibody response
but potentially also the glycosylation signature. Time between primary
exposure and subsequent re-encounters may be varied to assess waning
and boosting capacities. Fourthly, vaccination generally occurs in
healthy individuals and thus in the absence of a persisting systemic
inﬂammatory environment. In the absence of strong inﬂammatory
signals B-cells may be more strongly inﬂuenced by antigen properties,
rather than by the cytokine milieu. Fifthly, vaccination in healthy
adults does not conﬂict with any immune-modulating treatment regi-
mens, as may be the result in many individuals treated for auto-immune
diseases.
Given the strong advantages and feasibility of monitoring antigen-
speciﬁc antibody glycosylation in a vaccination setting in humans, it is
surprising to see how limited the studies into this area have been thus
far. The limited number of studies that have been performed do conﬁrm
the interesting patterns of antigen speciﬁc antibodies induced by vac-
cination and strongly support further investigation of the glycan re-
pertoire of antigen speciﬁc IgG following vaccination. However, given
the natural variation in IgG-Fc glycosylation between sexes, but also
during normal physiological processes such as ageing and pregnancies
as elaborated on above, vaccine studies should be carefully designed
and balanced (Fig. 5). Only then vaccine-induced changes in IgG Fc
glycosylation can be identiﬁed. Moreover, vaccination in infants and
young children may result in diﬀerent IgG glycan proﬁles as compared
to vaccination with the same combination of antigen and adjuvant in
adolescents, adults or the elderly. Therefore results from these studies
should be interpreted carefully, taking into consideration natural phy-
siological diﬀerences between the populations.
In mice, steady-state IgG glycosylation patterns already diﬀers be-
tween the IgG subclasses [34]. Moreover, not all IgG subclasses respond
with similar glycosylation changes to vaccination with the inﬂuenza
nucleoprotein antigen, such that not only pro and anti-inﬂammatory
signals but also IgG subclass determine which precise glycoforms are
induced [34]. T-cell independent vaccines (4-hydroxy-3-nitrophenyl)
acetyl - lipopolysaccharide (NP-LPS)) resulted in a stronger induction of
sialylated antibodies in experimental vaccination studies [34]. High
level sialylation may reduce binding to activating Fc receptors and
Fig. 5. Factors that may aﬀect vaccine eﬃcacy. Vaccination
against infectious agents aims in the induction of antibodies
that subsequently contribute to elimination of the pathogen.
The function of these antibodies is shaped by the glycan re-
pertoire on the Fc portion of the antibody. Diﬀerent factors
may inﬂuence the glycosylation proﬁle of antibodies, both
host related factor such as age, gender and origin, in-
ﬂammatory status, as well as vaccine factors determine the
end result. Vaccine factors that may inﬂuence antibody in-
duction and modiﬁcation are poorly characterized but may
involve antigen, adjuvant, doses, administration routes and
the time window since vaccination.
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thereby result in reduced levels of pro-inﬂammatory signals. Similarly,
T-cell independent vaccination with the TNP (2,4,6-trinitrophenyl)
antigen in mice, induced suppressive sialylated antibodies, whereas T-
cell dependent antigen induced antibodies that lacked galactose and
sialic acids [91]. T-cell help in the presence of proinﬂammatory stimuli
(by Th1 and Th17) is also involved in the induction of proinﬂammatory
IgG responses [91]. T-cell dependent antigens in the presence of
proinﬂammatory stimuli resulted in IgG antibodies that lacked sialic
acids [91,92]. By contrast, if co-stimulatory immune activation signals
are lacking, antibodies are induced that contain sialic acids and thus
can mediate immunosuppressive functions.
Mice vaccinated with BSA (bovine serum albumin) in incomplete
Freund’s adjuvant initially had anti-BSA antibodies with low levels of
galactosylation, but when the titres decreased the antibodies were
found to contain more galactoses [93]. This indicates that time is also a
critical factor, in particular in the vaccination setting where antigen is
only present temporarily. It would have been interesting to boost these
animals and assess IgG galactosylation following secondary antigen
encounter. Others have shown that repeated vaccination with oval-
bumin (OVA), in the absence of adjuvant, resulted in antigen speciﬁc
fucose containing IgG antibodies, and that the degree of fucosylation
increased with repeated booster vaccinations [94]. However, no dif-
ferences in galactose, mannose or sialic acid were detected between the
diﬀerently boosted groups, and unfortunately no group that only re-
ceived the priming dose was included [94].
Non-human primates were vaccinated with HIV gp140 envelope
protein (Env) adjuvanted with alum, MF59 or adjuvant nanoemulsion
(ANE) in the absence or presence of TLR activators and antibody in-
duction assessed. Antibody titers were highest in animals vaccinated
with Env in alum+TLR7, MF59 or ANE+TLR4 ligand. Antibodies
induced by alum+TLR7 and MF59 had the highest avidity. Antibodies
induced by Env adjuvanted with MF59 maintained the highest titers
during follow up [95]. Serological analysis revealed clear diﬀerences
between the adjuvants that correlated with the functional capacities of
the antibodies [95].
Together, these animal studies illustrate that IgG subclasses respond
diﬀerently to vaccination, antigen, adjuvant, number of doses, the en-
vironment and the time since vaccination, and that all these factors an
inﬂuence the resulting glycosylation signature. However, all studies
report rather anecdotal analyses and this ﬁeld would beneﬁt from more
systematic analysis of the glycan repertoire as a result of vaccination.
Comparison of human volunteers vaccinated with meningococcal,
pneumococcal or inﬂuenza vaccines revealed diﬀerent glycosylation
responses for the IgG subclasses depending on the vaccine. Global Fc
glycosylation proﬁles were not altered by vaccination [96]. In a small
group of humans, 2 inﬂuenza vaccines were compared, a pandemic
inﬂuenza vaccine adjuvanted with squalene and a seasonal inﬂuenza
vaccine without adjuvant [96]. The vaccine adjuvanted with squalene
induced fewer glycoforms and these glycoforms were less complex [96].
In the same study an adjuvanted meningococcal vaccine (Al(OH)3) did
not show the same eﬀects, indicating that adjuvants may have speciﬁc
eﬀects on glycosylation. Although the numbers of individuals were
highly limited, repeated annual vaccination against inﬂuenza seemed
not to inﬂuence the complexity of IgG glycosylation [96]. The presence
or absence of speciﬁc glycan groups such as fucoses will determine
functional properties, e.g. the presence of fucoses greatly diminishes
ADCC. Although functional assessments were not performed in this
study diﬀerences in fucosylation suggest diﬀerences in functional ca-
pacities [96].
Moreover, the IgG1 Fc glycosylation repertoire was assessed fol-
lowing vaccination with the MF59 adjuvanted inﬂuenza vaccine in
adults [97]. Vaccine speciﬁc IgG1 antibodies had increased levels of
galactosylation and sialylation, but decreased bisecting GlcNAc [97].
The number of sialic acids per galactose increased over time post vac-
cination [97]. Again, functional implications of these results were not
assessed and the number of samples analysed is limited and relatively
heterogeneous.
Glycosylation of Fc IgG1 was assessed upon vaccination with the
trivalent inactivated inﬂuenza vaccine. Sialic acid on IgG1 peaked at
day 7 post vaccination, after which it decreased again, but persisted at
higher levels compared to pre-vaccination [50]. In contrast, fucose was
consistently present on IgG1 molecules after vaccination. Galactose also
peaked at day 7 but returned to baseline afterwards, while no regula-
tion of bisected GlcNac was observed [50]. The presence of sialic acid
on the IgG1 molecules correlated with the aﬃnity for antigen on week 3
post vaccination [50].
Vaccination with the trivalent inﬂuenza vaccine was found not to
alter the total IgG glycosylation proﬁle [98]. However, if the glycosy-
lation repertoire was analysed in responders compared to non-re-
sponders important diﬀerences were identiﬁed. Responders had in-
creased levels of galactosylation of the bisected glycans and high
mannose containing glycoforms [98]. The glycosylation diﬀerences
observed may be used as predictive biomarkers of vaccine responsive-
ness as they were already detectable prior to vaccination and persisted
post vaccination [98].
Natural antibodies against HIV have been analysed in great detail
for their variation in Fc glycosylation and antiviral activity.
Intriguingly, HIV status and the capacity to control viral replication was
associated with changes in total Fc IgG glycosylation [74]. Spontaneous
control of HIV was associated with a shift towards agalactosylated
glycoforms for the total IgG fraction. This was much more prominent
among HIV speciﬁc antibodies (gp120), that had a greater frequency of
antibodies that lacked galactoses, fucoses and sialic acids [74]. The
glycoforms of these gp120 speciﬁc antibodies resulted in enhanced Fc
mediated viral control [74]. Diﬀerent antigens may evoke either more
or less immune activating glycosylation proﬁles: during HIV infection
p24 speciﬁc antibodies expressed more of the highly inﬂammatory
agalactosyated glycan as compared to gp120 speciﬁc antibodies [18].
In contrast, vaccination of HIV negative individuals with diﬀerent
formulations of the gp120 antigen elicited diﬀerently glycosylated IgGs.
Gp120 presented in an adenoviral vector was compared to gp120 ad-
juvanted with alum [18]. Indeed, signiﬁcant diﬀerences were identiﬁed
in glycosylation proﬁles between the diﬀerently adjuvanted vaccines.
Gp120 speciﬁc antibodies elicited by adenoviral vectors had higher
proportions of di-galactosylated and sialylated glycans, ﬁtting with a
more anti-inﬂammatory proﬁle. Moreover, the viral vectored vaccine
elicited increased proportions of bisected glycan structures [18]. Bi-
sected glycans in general have been reported to elicit greater ADCC
activity [99], but this has not been shown speciﬁcally for these ade-
noviral vector elicited gp120 speciﬁc antibodies. Combined, the viral
vector induced antibodies that activate less inﬂammatory antibody
glycosylation patterns but very eﬃcient viral elimination [18]. In-
triguingly, the glycan proﬁle of the vaccine induced antibodies was
completely diﬀerent from the antibodies involved in control following
natural infection. The same antigen thus can trigger completely dif-
ferent Ab glycan proﬁles depending on the context, either infection or
vaccination, modiﬁed by the type of vaccine/adjuvant, indicating reg-
ulation of glycosylation in vivo by the environment.
In summary, vaccination oﬀers a highly interesting clinical human
model to study and dissect the diﬀerent aspects that contribute to the
induction, diversiﬁcation as well as the persistence of (human) IgG Fc
glycosylation patterns, which has been underexplored. We strongly
support more in depth analysis of vaccine induced glycosylation pro-
ﬁles, not only to understand the protective eﬃcacy of speciﬁc vaccines
but also to explore the mechanisms, regulation and stability of IgG
glycosylation (Fig. 5). The limited amount of data available to date
suggest that subtle changes are functionally highly signiﬁcant.
7. Summary and future perspective
Immunoglobulins and in particular IgG undergo dynamic post-
translational modiﬁcations, glycosylations, that strongly inﬂuence
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secretion, stability, solubility, conformation and biological activity.
Since the process of glycosylation is highly dynamic and determined by
individual B-cells in response to the environment, IgG glycosylation
responses may be functionally very diﬀerent even for antibodies with
the same speciﬁcity. Natural variation in IgG Fc glycosylation occurs
between sexes, but also during ageing and pregnancies. Inﬂammatory
conditions such as autoimmune diseases but also chronic persisting
infections may further contribute to modiﬁcation of glycosylation
proﬁles.
Diversity in glycosylation proﬁles may aﬀect both the inﬂammatory
as well as the functional properties of the antibody (Fig. 6). Agalacto-
sylated antibodies are increased in inﬂammatory diseases, whereas
antibodies with sialic acids are associated with anti-inﬂammatory
functions and the presence of fucose is associated with ADCC and
subsequent phagocytosis (Fig. 6). Expression of glycosyl transferases
and other enzymes involved in glycosylation is regulated by B-cells
individually. However, it is unknown how the glycosylation machinery
of individual B-cells is regulated, it may be inﬂuenced by many factors
including host metabolism, sugar abundance, Golgi function and other
factors, and may very well respond to inﬂammatory signals in the en-
vironment. Therefore comparison of antibody responses against the
same antigen in the context of infection or vaccination may result in
highly diﬀerent glycan proﬁles. Similarly, treatment of inﬂammatory
ﬂares in autoimmune diseases may signiﬁcantly alter the glycan re-
pertoire irrespective of antigen speciﬁcity. Antibody glycosylation
proﬁles and subsequent functional properties have mostly been in-
vestigated in auto-immune diseases, for antibodies speciﬁc to auto-an-
tigens and under strong inﬂammatory conditions. However, antibody
responses to neo-antigens such as those derived from pathogens have
received only limited attention (Fig. 6). Glycosylation proﬁles of anti-
bodies to pathogen derived antigens may not only be diﬀerent because
the antibodies are directed against neo-antigens but also the in-
ﬂammatory signals are diﬀerent. Infections generally result in activa-
tion of danger signals such as triggering of Toll-like receptors (TLR) or
Nod-like receptors (NLR). Ligation of these pathways may strongly alter
glycosylation capacities of individual B-cells. Moreover, vaccination is
absolutely under-explored in this setting (Fig. 6). Although it is un-
certain which parts of the biological phenomenon of glycosylation can
be controlled for in future studies, understanding the rules of natural
Fc-engineering and it’s relation to function could provide a path to
actively leverage the full biology of the humoral immune response.
Vaccination studies may be instrumental to explore the eﬀect of antigen
speciﬁcity on immunoglobulin eﬀector functions. In a vaccination
context, antigens can be administered at dedicated times points, per-
mitting kinetic analyses, with variation in dose, route, interval and the
number of boosts. Vaccine antigens can be administered in the absence
or presence of a variety of adjuvants, including live viral vectors or
isolated TLR ligands to provide variable inﬂammatory conditions.
In conclusion, modiﬁcations in antibody glycosylation repertoires
seem highly relevant for the functional capacity of the antibodies and
thus should be incorporated in the assessment of antibody properties.
Antibody glycosylation proﬁles have been quite well established in
autoimmune diseases and monoclonal antibody therapies, however in
the ﬁeld of infectious diseases and vaccination much work as yet needs
to be done. We expect that this will not only guide the design of im-
proved vaccines, but will also yield signiﬁcant biological and me-
chanistic insights into regulation of antibody glycosylation and func-
tional signiﬁcance of these modiﬁcations.
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